Ovarian Neoplasms  >>  pegylated liposomal doxorubicin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
pegylated liposomal doxorubicin / Generic mfg.
NCT00653952: CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Terminated
3
220
US
CAELYX, Paclitaxel HCl
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Sequus Pharmaceuticals, ALZA
Ovarian Neoplasms
 
04/00
NCT00191607: A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Completed
3
162
US
Gemcitabine, liposomal doxorubicin
Eli Lilly and Company
Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms
 
11/05
NCT00057720: TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Completed
3
440
Europe, US, RoW
TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection
Telik
Ovarian Neoplasms
12/06
12/06
NCT00102973: TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

Completed
3
244
US
TLK286 in Combination with Carboplatin, Doxorubicin HCl Liposome Injection
Telik
Ovarian Neoplasms
07/08
07/08
ASSIST-5, NCT00350948 / 2006-000366-36: Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

Terminated
3
244
US, Europe, RoW
Telcyta, TLK286, canfosfamide, Liposomal Doxorubicin, Doxil, Caelyx
Telik
Ovarian Neoplasms
12/08
12/08
CALYPSO, NCT00189553: Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse

Completed
3
976
Europe
Pegylated liposomal doxorubicin, Caelyx, Carboplatin, generic drug, Paclitaxel
ARCAGY/ GINECO GROUP, Schering-Plough, Arbeitsgemeinschaft Gynaekologische Onkologie Austria, AGO Study Group, Australia New Zealand Gynaecological Oncology Group, European Organisation for Research and Treatment of Cancer - EORTC, NCIC Clinical Trials Group, NSGO
Ovarian Cancer, Fallopian Tube Cancer
01/09
06/12
ET743-OVA-301, NCT00113607 / 2004-005276-16: An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Completed
3
672
US, Canada, Europe, RoW
Trabectedin, Yondelis, DOXIL, CAELYX, Dexamethasone
Johnson & Johnson Pharmaceutical Research & Development, L.L.C., PharmaMar
Ovarian Cancer
11/10
11/10
NCT01840943: A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Terminated
3
32
RoW
CAELYX, Topotecan HCl
Xian-Janssen Pharmaceutical Ltd.
Epithelial Ovarian Cancer
05/14
08/14
TRINOVA-2, NCT01281254 / 2009-017946-30: AMG 386 (Trebananib) in Ovarian Cancer

Checkmark P3 trial (TRINOVA-2) enrollment discontinued due to Doxil supply issues
Mar 2014 - Mar 2014: P3 trial (TRINOVA-2) enrollment discontinued due to Doxil supply issues
Terminated
3
223
US, Canada, Europe, RoW
AMG386 plus PLD, Placebo plus PLD
Amgen
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
08/14
04/17
NCT01846611 / 2012-004808-34: A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed
3
581
US, Europe, RoW
Trabectedin, DOXIL, Dexamethasone
Janssen Research & Development, LLC, PharmaMar
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
01/18
11/18

Download Options